press_release_conclusion: Researchers from the University of Leicester and Leicester’s Hospitals have announced a breakthrough advance in the results of the world-first clinical trial with actual patients of a new drug to treat particular blood cancers.
abstract_conclusion: ONO/GS-4059 has significant activity in relapsed/refractory B-cell malignancies without major drug-related toxicity.